If the stock remains under $1 this week it will generate a deficiency notice from Nasdaq and will need to be above $1 by mid June to avoid delisting. With a small amount of outstanding shares it will be difficult to do a reverse split and maintain the 1.1M share outstanding requirement of Nasdaq. That being said, if preliminary results of the stage 2 tests are positive, this stock may be a huge winner. The combination with the NWBO vaccine technology may be a a life changer for GBM patients and shareholders of either or both companies.
Market Data 
Markets 
AI
